Birgitte Holst

Development of a dual neurotensin–GLP-1 co-agonist for obesity management

Applicant

Birgitte Holst

Project drescription

Obesity is a serious chronic disease with severe co-morbidities, such as cardiovascular diseases and fatty liver disease. Over the past decade, notable progress has been achieved in developing effective pharmacotherapies for weight loss, yet adverse side effects remain a major limitation, preventing patients from experiencing the full benefits of treatment. This proposal introduces an innovative strategy designed to harness the synergistic effects of GLP-1 and neurotensin, aiming to achieve superior and sustained weight loss along with cardiovascular benefits, while minimizing side effects, particularly gastrointestinal disturbances. With extensive expertise in medicinal chemistry, drug discovery, development, and pharmacological profiling, we are well-positioned to create a balanced co-agonist that unites the benefits of both GLP- 1 and neurotensin in a single molecule, while preserving optimal physio/chemical properties. Our novel treatment approach represents a promising step forward in delivering better therapeutic options for individuals struggling with overweight and obesity

Institution

University of Copenhagen